Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBTC Study 24: Intermittent REZ Regimen for Isoniazid-Resistant Tuberculosis
NCT00023374Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Aug 2000
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of rifampicin, ethambutol and pyrazinamide in Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Combined endpoint of bacteriologic plus clinical failure and relapse at 30 months. Started Aug 2000; status: completed.
02
Drugs
rifampicinethambutolpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00023374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023374.